83 related articles for article (PubMed ID: 19419786)
21. Homocysteine: an activity marker in Behçet's disease?
Sarican T; Ayabakan H; Turkmen S; Kalaslioglu V; Baran F; Yenice N
J Dermatol Sci; 2007 Feb; 45(2):121-6. PubMed ID: 17182219
[TBL] [Abstract][Full Text] [Related]
22. Homocysteine and arterial thrombosis: Challenge and opportunity.
Di Minno MN; Tremoli E; Coppola A; Lupoli R; Di Minno G
Thromb Haemost; 2010 May; 103(5):942-61. PubMed ID: 20352150
[TBL] [Abstract][Full Text] [Related]
23. Serum paraoxonase status: a major factor in determining resistance to organophosphates.
Li WF; Costa LG; Furlong CE
J Toxicol Environ Health; 1993; 40(2-3):337-46. PubMed ID: 7693961
[TBL] [Abstract][Full Text] [Related]
24. Homocysteine in vascular Behcet disease: a meta-analysis.
La Regina M; Orlandini F; Prisco D; Dentali F
Arterioscler Thromb Vasc Biol; 2010 Oct; 30(10):2067-74. PubMed ID: 20634474
[TBL] [Abstract][Full Text] [Related]
25. Hyperhomocysteinemia as a cardiovascular risk factor in Indian women: determinants and directionality.
Pandey SN; Vaidya AD; Vaidya RA; Talwalkar S
J Assoc Physicians India; 2006 Oct; 54():769-74. PubMed ID: 17214272
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the relationship between C677T variants of methylenetetrahydrofolate reductase gene and hyperhomocysteinemia in children receiving antiepileptic drug therapy.
Vurucu S; Demirkaya E; Kul M; Unay B; Gul D; Akin R; Gokçay E
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):844-8. PubMed ID: 18234410
[TBL] [Abstract][Full Text] [Related]
27. Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases.
Stanger O; Herrmann W; Pietrzik K; Fowler B; Geisel J; Dierkes J; Weger M
Z Kardiol; 2004 Jun; 93(6):439-53. PubMed ID: 15252738
[TBL] [Abstract][Full Text] [Related]
28. Differential hydrolysis of homocysteine thiolactone by purified human serum (192)Q and (192)R PON1 isoenzymes.
Bayrak A; Bayrak T; Demirpençe E; Kılınç K
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jan; 879(1):49-55. PubMed ID: 21123122
[TBL] [Abstract][Full Text] [Related]
29. [Hyperhomocysteinemia and deep-vein thrombosis].
Qiu L; Yan SK; Song YH
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Dec; 25(6):706-9. PubMed ID: 14714317
[TBL] [Abstract][Full Text] [Related]
30. Relationship between human paraoxonase-1 activity and PON1 polymorphisms in Mexican workers exposed to organophosphate pesticides.
López-Flores I; Lacasaña M; Blanco-Muñoz J; Aguilar-Garduño C; Sanchez-Villegas P; Pérez-Méndez OA; Gamboa-Avila R
Toxicol Lett; 2009 Jul; 188(2):84-90. PubMed ID: 19446239
[TBL] [Abstract][Full Text] [Related]
31. Homocysteine and arterial occlusive disease: a concise review.
Andreotti F; Burzotta F; Mazza A; Manzoli A; Robinson K; Maseri A
Cardiologia; 1999 Apr; 44(4):341-5. PubMed ID: 10371785
[TBL] [Abstract][Full Text] [Related]
32. Paraoxonase-1 (PON-1) genotype and activity and in vivo oxidized plasma low-density lipoprotein in Type II diabetes.
Sampson MJ; Braschi S; Willis G; Astley SB
Clin Sci (Lond); 2005 Aug; 109(2):189-97. PubMed ID: 15853770
[TBL] [Abstract][Full Text] [Related]
33. A mathematical model for evaluating the reaction of paraoxon with human serum cholinesterase and with polymorphic forms of paraoxonase.
Eckerson HW; La Du BN
Drug Metab Dispos; 1984; 12(1):57-62. PubMed ID: 6141913
[TBL] [Abstract][Full Text] [Related]
34. Effect of insulin resistance on serum paraoxonase activity in a nondiabetic population.
Yamada A; Shoji T; Tahara H; Emoto M; Nishizawa Y
Metabolism; 2001 Jul; 50(7):805-11. PubMed ID: 11436186
[TBL] [Abstract][Full Text] [Related]
35. Validation of a paraoxon-based method for measurement of paraoxonase (PON-1) activity and establishment of RIs in horses.
Ruggerone B; Bonelli F; Nocera I; Paltrinieri S; Giordano A; Sgorbini M
Vet Clin Pathol; 2018 Mar; 47(1):69-77. PubMed ID: 29575140
[TBL] [Abstract][Full Text] [Related]
36. Hyperhomocysteinemia in children on renal replacement therapy.
Feinstein S; Sela BA; Drukker A; Becker-Cohen R; Raveh D; Gavendo S; Frishberg Y
Pediatr Nephrol; 2002 Jul; 17(7):515-9. PubMed ID: 12172765
[TBL] [Abstract][Full Text] [Related]
37. Hyperhomocysteinemia: an additional cardiovascular risk factor.
Fanapour PC; Yug B; Kochar MS
WMJ; 1999 Dec; 98(8):51-4. PubMed ID: 10639897
[TBL] [Abstract][Full Text] [Related]
38. [Effects of intervention therapy of methylcobalamin and folic acid on plasma homocysteine concentration and homocysteine thiolactonases/paraoxonase activity in patients with type 2 diabetes mellitus].
Gu WJ; Lu JM; Yang GQ; Guo QH; Dou JT; Mu YM; Pan CY
Zhonghua Yi Xue Za Zhi; 2007 Jan; 87(4):256-8. PubMed ID: 17425871
[TBL] [Abstract][Full Text] [Related]
39. Homocysteine and serum markers of immune activation in primary dystonia.
Muller UJ; Frick B; Winkler C; Fuchs D; Wenning GK; Poewe W; Mueller J
Mov Disord; 2005 Dec; 20(12):1663-7. PubMed ID: 16108020
[TBL] [Abstract][Full Text] [Related]
40. The risk of venous and arterial thrombosis in hyperhomocysteinemic subjects may be a result of elevated factor VIII levels.
Lijfering WM; Veeger NJ; Brouwer JL; van der Meer J
Haematologica; 2007 Dec; 92(12):1703-6. PubMed ID: 18055997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
